EARLY NONINVASIVE EVALUATION OF LIVER FIBROSIS AFTER HEPATITIS C TREATMENT: THE IMPACT OF INFLAMMATION.

Q2 Medicine Arquivos de Gastroenterologia Pub Date : 2024-12-20 eCollection Date: 2024-01-01 DOI:10.1590/S0004-2803.24612024-043
João Batista Xavier, Joel Schmillevitch, Christini Emori, Silvia Uehara, Eunice Jadriana Nunes, Maria Lucia Ferraz
{"title":"EARLY NONINVASIVE EVALUATION OF LIVER FIBROSIS AFTER HEPATITIS C TREATMENT: THE IMPACT OF INFLAMMATION.","authors":"João Batista Xavier, Joel Schmillevitch, Christini Emori, Silvia Uehara, Eunice Jadriana Nunes, Maria Lucia Ferraz","doi":"10.1590/S0004-2803.24612024-043","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).</p><p><strong>Objective: </strong>To evaluate hepatic fibrosis using ARFI technology before and after successive treatments for chronic HCV.</p><p><strong>Methods: </strong>We prospectively included 50 adult patients with chronic HCV (genotype 1). Patients were first submitted to triple therapy with first-generation protease inhibitors (boceprevir and telaprevir) at the hepatitis division of the Gastroenterology Department of the Federal University of São Paulo. The non-responders underwent re-treatment with interferon-free direct-acting antiviral agents (DDAs - sofosbuvir associated with daclatasvir or simeprevir). Assessment of hepatic stiffness by ARFI was performed before and after the first treatment and before and after the re-treatment with DDAs.</p><p><strong>Results: </strong>ARFI values decreased significantly after treatments. In patients on first-generation protease inhibitor therapy and achieving sustained virological response (SVR), ARFI decreased from 2.41±0.58 pre-treatment to 2.02+/-0.58 (P<0.042) post-treatment. In patients who did not reach SVR, that is, non-responders, a significant reduction was similarly observed (2.39±0.63 to 2.03±0.54; P<0.001 before and after treatment, respectively). Before starting the re-treatment, non-responders had elevated ARFI values again, dropping after SVR following re-treatment (from 2.46±0.57 to 1.45±0.68, P<0.004). Laboratory parameters such as AST and ALT were directly correlated to ARFI elastography.</p><p><strong>Conclusion: </strong>The evaluation of hepatic elastography by the ARFI method before and after (6 - 9 months) successive treatment of hepatitis C in responders and non-responders led to the conclusion that the reduction of elastography parameters seems to be related to a decrease in hepatic inflammation rather than a reduction in fibrosis per se.</p>","PeriodicalId":35671,"journal":{"name":"Arquivos de Gastroenterologia","volume":"61 ","pages":"e24043"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos de Gastroenterologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S0004-2803.24612024-043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Liver biopsy (LB) is still the gold standard method for assessing hepatic fibrosis (HF), associated diseases, and liver inflammation. Nowadays, noninvasive techniques such as Acoustic radiation force impulse (ARFI) elastography have been introduced instead of liver biopsy. However, there are controversies about the time it should be performed after treatment for hepatitis C virus (HCV).

Objective: To evaluate hepatic fibrosis using ARFI technology before and after successive treatments for chronic HCV.

Methods: We prospectively included 50 adult patients with chronic HCV (genotype 1). Patients were first submitted to triple therapy with first-generation protease inhibitors (boceprevir and telaprevir) at the hepatitis division of the Gastroenterology Department of the Federal University of São Paulo. The non-responders underwent re-treatment with interferon-free direct-acting antiviral agents (DDAs - sofosbuvir associated with daclatasvir or simeprevir). Assessment of hepatic stiffness by ARFI was performed before and after the first treatment and before and after the re-treatment with DDAs.

Results: ARFI values decreased significantly after treatments. In patients on first-generation protease inhibitor therapy and achieving sustained virological response (SVR), ARFI decreased from 2.41±0.58 pre-treatment to 2.02+/-0.58 (P<0.042) post-treatment. In patients who did not reach SVR, that is, non-responders, a significant reduction was similarly observed (2.39±0.63 to 2.03±0.54; P<0.001 before and after treatment, respectively). Before starting the re-treatment, non-responders had elevated ARFI values again, dropping after SVR following re-treatment (from 2.46±0.57 to 1.45±0.68, P<0.004). Laboratory parameters such as AST and ALT were directly correlated to ARFI elastography.

Conclusion: The evaluation of hepatic elastography by the ARFI method before and after (6 - 9 months) successive treatment of hepatitis C in responders and non-responders led to the conclusion that the reduction of elastography parameters seems to be related to a decrease in hepatic inflammation rather than a reduction in fibrosis per se.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
丙型肝炎治疗后肝纤维化的早期无创评估:炎症的影响。
背景:肝活检(LB)仍然是评估肝纤维化(HF)、相关疾病和肝脏炎症的金标准方法。目前,无创技术如声辐射力脉冲(ARFI)弹性成像已经取代肝脏活检。然而,对于丙型肝炎病毒(HCV)治疗后应在何时进行该手术存在争议。目的:应用ARFI技术评价慢性丙型肝炎连续治疗前后肝纤维化情况。方法:我们前瞻性地纳入了50例慢性HCV(基因型1)的成年患者。患者首先在圣保罗联邦大学消化内科肝炎科接受第一代蛋白酶抑制剂(boceprevir和telaprevir)的三联治疗。无应答者接受无干扰素直接作用抗病毒药物(DDAs - sofosbuvir联合daclatasvir或simeprevir)的再次治疗。第一次治疗前后和dda再治疗前后分别用ARFI评估肝脏僵硬度。结果:治疗后ARFI值明显降低。在接受第一代蛋白酶抑制剂治疗并获得持续病毒学应答(SVR)的患者中,ARFI从治疗前的2.41±0.58降至2.02+/-0.58 (p)。在对丙型肝炎有反应者和无反应者进行连续治疗前后(6 - 9个月)用ARFI方法对肝弹性成像的评估得出结论,弹性成像参数的减少似乎与肝脏炎症的减少有关,而不是纤维化本身的减少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Arquivos de Gastroenterologia
Arquivos de Gastroenterologia Medicine-Gastroenterology
CiteScore
2.00
自引率
0.00%
发文量
109
审稿时长
9 weeks
期刊介绍: The journal Arquivos de Gastroenterologia (Archives of Gastroenterology), a quarterly journal, is the Official Publication of the Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia IBEPEGE (Brazilian Institute for Studies and Research in Gastroenterology), Colégio Brasileiro de Cirurgia Digestiva - CBCD (Brazilian College of Digestive Surgery) and of the Sociedade Brasileira de Motilidade Digestiva - SBMD (Brazilian Digestive Motility Society). It is dedicated to the publishing of scientific papers by national and foreign researchers who are in agreement with the aim of the journal as well as with its editorial policies.
期刊最新文献
PEDIATRIC CHOLELITHIASIS AND FACTORS ASSOCIATED WITH CHOLECYSTECTOMY. DIAGNOSIS AND TREATMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH: AN OFFICIAL POSITION PAPER FROM THE BRAZILIAN FEDERATION OF GASTROENTEROLOGY. A GLOBAL VIEW OF HEPATOLOGY COLLABORATION: INSIGHTS AND FUTURE DIRECTIONS FROM 30 YEARS OF NETWORK ANALYSIS (1994-2023). A POSSIBLE ROLE OF HEPCIDIN IN INTESTINAL INFLAMMATION. ASSOCIATION OF "METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC PANCREAS DISEASE" (MASPD) AND INSULIN RESISTANCE.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1